|
08/11/2022
|
Summary ToggleEledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results
|
|
08/04/2022
|
Summary ToggleEledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
|
|
08/01/2022
|
Summary ToggleEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
|
|
07/18/2022
|
Summary ToggleEledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation
|
|
06/10/2022
|
Summary ToggleEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
06/09/2022
|
Summary ToggleEledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation
|
|
06/02/2022
|
Summary ToggleEledon Pharmaceuticals to Present at the Jefferies Healthcare Conference
|
|
05/31/2022
|
Summary ToggleEledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
|
|
05/12/2022
|
Summary ToggleEledon Pharmaceuticals Reports First Quarter 2022 Operating and Financial Results
|
|
05/09/2022
|
Summary ToggleEledon Pharmaceuticals Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy
|
